Breaking News

Our March STAT+ benefits

STAT

www.statnews.com/stat-plus

Subscribe to STAT+ and access exclusive benefits 

When you're a STAT+ subscriber, you get to enjoy perks like discounts on our STAT Reports and events, free access to our new CRISPR TRACKR, as well as in-depth daily coverage and analysis of the biotech, pharma, and health tech industries and exclusive newsletters. Subscribe today to join our community.

JOIN STAT+


Here's what STAT+ subscribers can access this month

Taking the pulse of clinical trials

Date: Thursday, March 17, 2022
Time: 1:00 p.m. ET
Keeping track of clinical trials is a Herculean task, as millions of changes occur each year. STAT Trials Pulse is a new clinical intelligence platform that can help, allowing users to seamlessly keep tabs on the trials they care about, and find actionable insights that can drive a company’s strategic and financial direction. Join experts at STAT for a discussion about how to use this new tool, developed in conjunction with Applied XL, to make sense of clinical trials data.

REGISTER

The STAT Breakthrough Science Summit

Date: Thursday, March 31, 2022
Time: 9:00 a.m. - 5:30 p.m. ET
This full-day event will give you an inside look at the technologies and procedures at the cutting edge of health and medicine. With STAT reporters leading the conversations, you’ll hear from executives, researchers, scientists, and investors and learn about the latest efforts to battle diseases and help patients. You can be a part of our Summit virtually, or apply to attend in person.

STAT+ Subscribers can unlock a 20% discount with the STAT+ Subscriber Viewer Pass. 

REGISTER

STAT Trials Pulse

STAT Trials Pulse is a new clinical trials intelligence platform, built by AI company Applied XL and vetted by STAT’s national biotech team, that helps life sciences professionals identify the most important updates happening in the clinical trial space.

Become a STAT+ subscriber to unlock a 15% discount on an annual membership.

Start Free Trial

New: STAT+ Group Subscription

A STAT+ Group Subscription allows groups of two to 10 users to purchase a subscription at discounted rates. With a group subscription, you can enjoy the same service as an individual subscription, plus dedicated customer support, centralized payment options, and the comfort of knowing that your team is on the same page. There’s no obligation—you can cancel at any time or swap users in and out as needed.

Get started

Announcing the 2022 STATUS List

Meet the STATUS List — 46 individuals shaping the future of their fields. Drawn from sectors including biotechnology and diagnostics, as well as broader arenas like education and policy, each individual has taken extra steps to help others and build community in these often-divisive times.

Explore the list


STAT+ Reads

In case you missed them, here are some of our favorite STAT+ stories from this past month:

Read more 


Still on the fence? Get to know our team.

We have a few free events and products that you can check out. They'll  help you get to know the STAT+ team a little better before you invest in a subscription.

New Season: First Opinion Podcast

Released Wednesdays starting March 16
Listen in each week as STAT’s First Opinion editor, Pat Skerrett, hosts people who have compelling perspectives on the ideas that are shaping health, medicine, and scientific discovery.

Listen

AACR in 30 Seconds

Delivered April 8–11, 2022
STAT will attend the American Association for Cancer Research annual meeting for you. Get the analysis about the news you'll need to know from the conference with this pop-up newsletter.

Register

STAT E-Books

Unlock story collections with our free e-books. STAT’s award winning editors compile these collections of the most hard hitting stories for you to delve deeper into what matters.

View All

Thursday, March 10, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments